923020-93-3

Basic information

• Product Name: 4H-Pyran-4,4-dicarboxylic acid, tetrahydro-, 4-methyl ester
• Synonyms: 4H-Pyran-4,4-dicarboxylic acid,tetrahydro-,4-methyl ester;tetrahydropyran-4,4-dicarboxylic acid monomethylester
• CAS NO: 923020-93-3
• Molecular Formula: C8H12O5
• Molecular Weight: 187.17000
• Mol File: 923020-93-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4H-Pyran-4,4-dicarboxylic acid, tetrahydro-, 4-methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyran-4,4-dicarboxylic acid, tetrahydro-, 4-methyl ester(923020-93-3)
• EPA Substance Registry System: 4H-Pyran-4,4-dicarboxylic acid, tetrahydro-, 4-methyl ester(923020-93-3)

Safety Data

• Hazardous Substances Data: 923020-93-3(Hazardous Substances Data)

Usage

Chemical compound

4H-Pyran-4,4-dicarboxylic acid, tetrahydro-, 4-methyl ester
Commonly used in the synthesis of pharmaceutical drugs and organic compounds
Methyl ester derivative of tetrahydro-4H-pyran-4,4-dicarboxylic acid
Known for high stability and low reactivity
Suitable building block for complex organic molecules
Used in manufacturing fragrances and flavorings
Used in the agricultural industry as a pesticide and insect repellent
Versatile compound with wide range of industrial applications

Upstream product

• 149777-00-4 4,4-dimethyl dihydro-2H-pyran-4,4(3H)-dicarboxylate 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 124-38-9 carbon dioxide 

Relevant articles and documents

Quinoline multi-target kinase inhibitor with antitumor activity and preparation method thereof

The invention relates to a quinoline multi-target kinase inhibitor with antitumor activity and a preparation method thereof. A general structural formula of the compound is shown in a formula (I) described in the specification. In vitro cell experiments verify that the compound provided by the invention has strong in vitro inhibitory activity on five common tumor cell lines, namely human thyroid carcinoma SW579, human hepatic carcinoma HepG2, human lung adenocarcinoma A549, human colorectal adenocarcinoma HCT116 and human gastric carcinoma MKN45, antitumor activities of most of target compounds are better than or equivalent to that of a positive control drug Cabozantinib, and the in vitro cell experiments verify that the compound provided by the invention has strong inhibitory activity on two kinases KDR and MET, so that the compound provided by the invention has a broad application prospect in preparation of a new antitumor drug.